The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Open accessAbstract
Histone deacetylases (HDACs) are enzymes pursued as drug targets in various cancers and several non-oncological conditions, such as inflammation and neurodegenerative disorders. In the past decade, HDAC inhibitors (HDACi) have emerged as relevant pharmaceuticals, with many efforts devoted to the development of new representatives. However, the growing safety concerns regarding the established hydroxamic acid-based HDAC inhibitors tend to drive current research more toward the design of inhibitors bearing alternative zinc-binding groups (ZBGs). This Perspective presents an overview of all non-hydroxamic acid ZBGs that have been incorporated into the clinically approved prototypical HDACi, suberoylanilide hydroxamic acid (vorinostat). This provides the unique opportunity to compare the inhibition potential and biological effects of different ZBGs in a direct way, as the compounds selected for this Perspective differ only in their ZBG. To that end, different strategies used to select a ZBG, its properties, activity, and liabilities are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While most HDACi tend to employ a hydroxamic acid as a ZBG, class I HDACs (particularly HDACs 1–3) tend to be the only class of HDACs inhibited by 2-amino anilides as a ZBG (Figure 4A) [9–13].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For this reason, RGFP966 (Figure 11) has emerged as the most frequently employed tool for HDAC3 pharmacologic inhibition in biological studies [9, 13, 67, 69–71].”
From Medicinal chemistry advances in targeting class I histone deacetylases (2023) · cites this paper as [13]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–206 of 206
Phosphorus containing analogues of SAHA as inhibitors of HDACs
Pun, M. D., Wu, H.-H., Olatunji, F. P., Kesic, B. N., Peters, J. W., & Berkman, C. E. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2063281 · Cited by 11
Quantum chemical study of silanediols as metal binding groups for metalloprotease inhibitors
Ignatyev, I. S., Montejo, M., Ortega, P. G. R., & González, J. J. L. (2013) · Journal of Molecular Modeling · doi:10.1007/s00894-012-1745-0 · Cited by 9
Depetter, Y., Geurs, S., Bussche, F. V., Vreese, R. D., Franceus, J., Desmet, T., Wever, O. D., & D’hooghe, M. (2018) · MedChemComm · doi:10.1039/c8md00107c · Cited by 9
Self-citationIslam, M. N., Islam, M. S., Hoque, M. A., Kato, T., Nishino, N., Ito, A., & Yoshida, M. (2014) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2014.10.003 · Cited by 6
Ortega, P. G. R., Montejo, M., & González, J. J. L. (2014) · Journal of Molecular Modeling · doi:10.1007/s00894-014-2430-2 · Cited by 4
(2019) · Journal of Chinese Pharmaceutical Sciences · doi:10.5246/jcps.2019.06.040 · Cited by 2
Flagged first, then by citations
Research works printed but not linked: 8
- Raedler L. A., 2016, Am. Health Drug Benefits, 9, 84
- 10.1007/s00894-018-3651-6 · DOI
- 10.1016/j.bmcl.2006.06.090 · DOI
- Vigushin D. M., 2001, Clin. Cancer Res., 7, 971
- 10.1021/jm900125m · DOI
- 10.1016/S0960-894X(02)00754-0 · DOI
- Furumai R., 2002, Cancer Res., 62, 4916
- Nelson S. D., 1978, J. Pharmacol. Exp. Ther., 206, 574
Cited by
Sorted by citations
The role of silicon in drug discovery: a review
Panayides, J., Riley, D. L., Hasenmaile, F., & van Otterlo, W. A. L. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00169a · Cited by 141
Raucci, A., Zwergel, C., Valente, S., & Mai, A. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01677 · Cited by 43
Ripa, L., Sandmark, J., Hughes, G. A., Shamovsky, I. L., Gunnarsson, A., Johansson, J., Llinàs, A., Collins, M., Jung, B., Novén, A., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01269 · Cited by 33
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Pires, G. S., Tolomeu, H. V., Rodrigues, D. A., Lima, L. M., Fraga, C. A. M., & Pinheiro, P. D. S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18040577 · Cited by 28
Adverse drug reaction profiles of histone deacetylase inhibitors
Begum, R., Parsons, J. L., & Jones, A. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-19717-w · Cited by 23
Metadata
- Authors
- Geurs, S., Clarisse, D., De Bosscher, K., & D’hooghe, M.
- Affiliations
- Ghent University (BE)
- Translational Nuclear Receptor Research, VIB-UGent Center for Medical Biotechnology, Technologiepark-Zwijnaarde 75, B-9052 Ghent, Belgium
- Corresponding author
- D’hooghe, Matthias
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2023-06-05
- Volume
- 66
- Issue
- 12
- Pages
- 7698-7729
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4379468009
- Cited by
- 58
- References
- 206
- Citations by year
- 2026: 20 · 2025: 19 · 2024: 14 · 2023: 5
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- green
- biblio.ugent.be
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Funders
- Fonds Wetenschappelijk Onderzoek
- Bijzonder Onderzoeksfonds UGent
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Enzyme function and inhibition
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- histone deacetylase inhibitors, vorinostat, zinc-binding groups, drug safety
- MeSH terms
- Vorinostat, Histone Deacetylases, Hydroxamic Acids, Zinc, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
